We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+21.69%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
+$274M
Cap. Flow
+$156M
Cap. Flow %
15.15%
Top 10 Hldgs %
40.17%
Holding
97
New
37
Increased
20
Reduced
20
Closed
12

Top Buys

1
HRTX icon
Heron Therapeutics
HRTX
+$29.8M
2
TVTX icon
Travere Therapeutics
TVTX
+$24.7M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$22.5M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$20.5M
5
EBS icon
Emergent Biosolutions
EBS
+$18.5M

Top Sells

1
LCI
Lannett Company, Inc.
LCI
+$25.5M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.4M
3
ASRT
Assertio
ASRT
+$19.7M
4
NVDQ
Novadaq Technologies Inc.
NVDQ
+$14.7M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$14.7M

Sector Composition

1 Healthcare 79.95%
2 Technology 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CARM
26
DELISTED
Carisma Therapeutics
CARM
$14M 1.36%
+43,097
New +$12.9M
DVAX
27
DELISTED
Dynavax Technologies
DVAX
$13.8M 1.34%
766,010
+41,010
+6% +$761K
ATRC icon
28
AtriCure
ATRC
$1.77B
$13.4M 1.3%
712,495
+275,000
+63% +$5.64M
ACGN
29
DELISTED
Aceragen Inc
ACGN
$13.1M 1.27%
23,558
-2,571
-10% -$1.76M
ELOS
30
DELISTED
Syneron Medical Ltd
ELOS
$12.5M 1.21%
1,005,221
+805,221
+403% +$9.54M
PETX
31
DELISTED
Aratana Therapeutics, Inc.
PETX
$12.4M 1.2%
+667,435
New +$13.4M
LBMH
32
DELISTED
LIBERATOR MED HLDGS INC (NY)
LBMH
$12M 1.16%
3,058,644
+889,113
+41% +$3.9M
AUXL
33
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
$11.2M 1.08%
411,100
-550,000
-57% -$14.6M
CEMP
34
DELISTED
Cempra, Inc.
CEMP
$11M 1.07%
955,147
-209,400
-18% -$2.6M
OCR
35
DELISTED
OMNICARE INC
OCR
$10.4M 1.01%
+175,000
New +$10.6M
MOH icon
36
Molina Healthcare
MOH
$11.7B
$10.3M 1%
275,000
+45,700
+20% +$1.68M
XNCR icon
37
Xencor
XNCR
$1.3B
$9.09M 0.88%
774,881
-99,119
-11% -$1.04M
SGNT
38
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$8.88M 0.86%
380,188
+58,800
+18% +$1.29M
POZN
39
DELISTED
POZEN INC
POZN
$8.66M 0.84%
1,083,087
-72,236
-6% -$592K
TLGT
40
DELISTED
Teligent, Inc
TLGT
$8.47M 0.82%
150,000
– –
ATRS
41
DELISTED
Antares Pharma, Inc.
ATRS
$8.05M 0.78%
2,300,000
+1,500,000
+188% +$6.66M
CCXI
42
DELISTED
ChemoCentryx, Inc.
CCXI
$6.96M 0.67%
1,050,000
+16,332
+2% +$113K
NGNE icon
43
Neurogene
NGNE
$744M
$6.5M 0.63%
+25,525
New +$6.56M
UAM
44
DELISTED
Universal American Corp
UAM
$6.23M 0.6%
+881,605
New +$6.25M
DRRX
45
DELISTED
DURECT Corp
DRRX
$5.86M 0.57%
440,450
-103,579
-19% -$1.81M
TENX icon
46
Tenax Therapeutics
TENX
$420M
$5.51M 0.53%
+31
New +$6.14M
AIRM
47
DELISTED
Air Methods Corp
AIRM
$5.34M 0.52%
+100,000
New +$5.34M
RXDX
48
DELISTED
Ignyta, Inc.
RXDX
$5.33M 0.52%
+641,700
New +$6.01M
NSTG
49
DELISTED
NanoString Technologies, Inc.
NSTG
$5.25M 0.51%
+254,068
New +$4.84M
TNXP icon
50
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Broadfin Capital held 97 positions worth $1.03B, up 36% from $758M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Broadfin Capital deployed $156M of net new capital in Q1 2014, opening 37 new positions and adding to 20 existing holdings. Its largest new stake was Heron Therapeutics: 2,233,173 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Lannett Company, Inc., an estimated $25.5M trimmed.

  • Broadfin Capital's largest Q1 2014 buy was Heron Therapeutics: 2,233,173 shares worth $31.1M.
  • Broadfin Capital added most to Emergent Biosolutions in Q1 2014, an estimated $18.5M increase.
  • Broadfin Capital's biggest Q1 2014 reduction was Lannett Company, Inc., cutting an estimated $25.5M.
  • Broadfin Capital fully exited NPS PHARMACEUTICALS INC in Q1 2014, selling an estimated $12.1M.
  • Broadfin Capital's ten largest holdings make up 40% of its $1.03B portfolio in Q1 2014.
  • Broadfin Capital opened 37 new positions and closed 12 in Q1 2014.
  • Broadfin Capital's portfolio value rose 36% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q1 2014, filed 15 May 2014.